Cognitive Impairment

Psychiatry·MeSH: Cognitive Dysfunction

16 drugs in development·13 companies·14 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
Kisunla	ELI LILLY & Co (LLY)
neuraceq	Lantheus Holdings, Inc. (LNTH)
vizamyl	GE HealthCare Technologies Inc. (GEHC)

Phase 3(1)

Drug	Company
canakinumab	Novartis AG (NVS)

Phase 2(3)

Drug	Company
nyx-458	Aptinyx Inc. (APTX)
RL-007	Atai Beckley N.V. (ATAI)
sabirnetug (ACU193)	Acumen Pharmaceuticals, Inc. (ABOS)

Phase 1(2)

Drug	Company
BIIB080	BIOGEN INC. (BIIB)
mk4334	Neuphoria Therapeutics Inc. (NEUP)

Preclinical(2)

Drug	Company
ALPHA-1062 intranasal (ALPHA-1062IN)	Alpha Cognition Inc. (ACOG)
alpha-1062 sublingual	Alpha Cognition Inc. (ACOG)

Unknown(1)

Drug	Company
nb-02	MetaVia Inc. (MTVA)

Phase 2/Phase 3(1)

Drug	Company
dalzanemdor	Sage Therapeutics, Inc. (SAGE)

Phase 4(3)

Drug	Company
canakinumab	Novartis AG (NVS)
metaxalone m640	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
tizanidine	ELITE PHARMACEUTICALS INC /NV/ (ELTP)

BioSniper tracks 16 drugs in development for Cognitive Impairment across 13 companies.

There are 14 clinical trials targeting Cognitive Impairment tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.